Wednesday, July 8, 2026

pharma · COVID-19 · Poliomyelitis

Sinovac Research and

SINOVAC BIOTECH (BANGLADESH) is a pharma organization headquartered in Dhaka, CN. Primary therapeutic focus areas include COVID-19, Poliomyelitis, Influenza, Hand, Foot and Mouth Disease, Varicella. NovaPharmaNews links

Dhaka, CN HQ
2022 Founded
9 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Dhaka, CN
Founded
2022
Employees
9
Programs
115
Drugs
54
Patents
0
Clinical program

SA55 Injection

Phase 1 · small molecule · COVID-19

SA55 Injection for COVID-19 is a Phase 1 program (small_molecule) at Sinovac Research and Development Co., with 1 ClinicalTrials.gov record(s).

Internal code PRO-SA55-1001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Sinovac Research and Development Co.,
Phase
Phase 1
Modality
small_molecule
Indication
COVID-19
Status
active
Trials
1